Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 9.67
NAS:FOLD's Cash to Debt is ranked lower than
58% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. NAS:FOLD: 9.67 )
Ranked among companies with meaningful Cash to Debt only.
NAS:FOLD' s Cash to Debt Range Over the Past 10 Years
Min: 3.28  Med: 48.48 Max: No Debt
Current: 9.67
Equity to Asset 0.37
NAS:FOLD's Equity to Asset is ranked lower than
81% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:FOLD: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
NAS:FOLD' s Equity to Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.49 Max: 0.84
Current: 0.37
0.28
0.84
F-Score: 4
Z-Score: -0.65
M-Score: 5.67
WACC vs ROIC
15.20%
-100.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -8362.62
NAS:FOLD's Operating margin (%) is ranked lower than
91% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. NAS:FOLD: -8362.62 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:FOLD' s Operating margin (%) Range Over the Past 10 Years
Min: -17680.72  Med: -1430.62 Max: -11.42
Current: -8362.62
-17680.72
-11.42
Net-margin (%) -8664.36
NAS:FOLD's Net-margin (%) is ranked lower than
91% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. NAS:FOLD: -8664.36 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:FOLD' s Net-margin (%) Range Over the Past 10 Years
Min: -16427.82  Med: -1286.28 Max: -10.2
Current: -8664.36
-16427.82
-10.2
ROE (%) -53.92
NAS:FOLD's ROE (%) is ranked lower than
63% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. NAS:FOLD: -53.92 )
Ranked among companies with meaningful ROE (%) only.
NAS:FOLD' s ROE (%) Range Over the Past 10 Years
Min: -322.07  Med: -82.09 Max: -9.19
Current: -53.92
-322.07
-9.19
ROA (%) -20.07
NAS:FOLD's ROA (%) is ranked higher than
58% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. NAS:FOLD: -20.07 )
Ranked among companies with meaningful ROA (%) only.
NAS:FOLD' s ROA (%) Range Over the Past 10 Years
Min: -104.95  Med: -44.78 Max: -6.13
Current: -20.07
-104.95
-6.13
ROC (Joel Greenblatt) (%) -2327.27
NAS:FOLD's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. NAS:FOLD: -2327.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:FOLD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2904.44  Med: -1385.29 Max: -134.99
Current: -2327.27
-2904.44
-134.99
Revenue Growth (3Y)(%) -100.00
NAS:FOLD's Revenue Growth (3Y)(%) is ranked lower than
97% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. NAS:FOLD: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:FOLD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -70.4 Max: -2.3
Current: -100
EBITDA Growth (3Y)(%) 2.00
NAS:FOLD's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. NAS:FOLD: 2.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:FOLD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.6  Med: -13.5 Max: 81.7
Current: 2
-85.6
81.7
EPS Growth (3Y)(%) 3.90
NAS:FOLD's EPS Growth (3Y)(%) is ranked higher than
58% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. NAS:FOLD: 3.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:FOLD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -85.2  Med: -14.2 Max: 54.5
Current: 3.9
-85.2
54.5
GuruFocus has detected 4 Warning Signs with Amicus Therapeutics Inc $NAS:FOLD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:FOLD's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

FOLD Guru Trades in Q1 2016

Paul Tudor Jones 16,950 sh (New)
RS Investment Management 3,527,703 sh (+1.11%)
Louis Moore Bacon Sold Out
Chuck Royce Sold Out
» More
Q2 2016

FOLD Guru Trades in Q2 2016

Paul Tudor Jones 72,981 sh (+330.57%)
RS Investment Management 3,429,187 sh (-2.79%)
» More
Q3 2016

FOLD Guru Trades in Q3 2016

Jim Simons 196,400 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

FOLD Guru Trades in Q4 2016

Paul Tudor Jones 51,290 sh (New)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:CLCD, NAS:ZIOP, NAS:CORT, NAS:AIMT, NAS:AMRN, NAS:EDIT, NAS:INSM, NAS:AMAG, OTCPK:BPMUF, NAS:AMRI, NAS:INSY, NAS:ADRO, NAS:AKAO, NAS:CLLS, NAS:GBT, NAS:XLRN, NAS:ANIP, NAS:MGNX, NAS:PGNX, NAS:EPZM » details
Traded in other countries:AM6.Germany,
Amicus Therapeutics Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of next-generation medicines for orphan diseases.

Amicus Therapeutics Inc incorporated under the laws of the State of Delaware on February 4, 2002. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). IT is focused on developing pharmacological chaperones as monotherapy agents (to be used without ERT) and its Chaperone- Advanced Replacement Therapy, or CHART platform of pharmacological chaperones in combination with ERT. Chaperone- Advanced Replacement Therapy, or CHART, platform has been used to develop our next-generation ERTs by co-formulating therapeutic enzymes with our proprietary pharmacological chaperones. It is also developing migalastat HCl as a monotherapy in two Phase 3 global registration studies ("Study 011" and "Study 012") for Fabry patients with genetic mutations that were amenable to this pharmacological chaperone in a cell-based assay. Study 011 is a 24-month study consisting of a 6-month double-blind, placebo-controlled treatment period (Stage 1); a 6-month open-label follow-up period (Stage 2); and a 12-month open-label extension phase. The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. Its competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for lysosomal storage disorders within core programs. The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design, AMICUS THERAPEUTICS and CHART.

Ratios

vs
industry
vs
history
P/B 2.65
FOLD's P/B is ranked higher than
63% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. FOLD: 2.65 )
Ranked among companies with meaningful P/B only.
FOLD' s P/B Range Over the Past 10 Years
Min: 0.87  Med: 3.18 Max: 14.52
Current: 2.65
0.87
14.52
P/S 418.00
FOLD's P/S is ranked lower than
92% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. FOLD: 418.00 )
Ranked among companies with meaningful P/S only.
FOLD' s P/S Range Over the Past 10 Years
Min: 0.84  Med: 29.95 Max: 4540
Current: 418
0.84
4540
EV-to-EBIT -3.90
FOLD's EV-to-EBIT is ranked lower than
99.99% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. FOLD: -3.90 )
Ranked among companies with meaningful EV-to-EBIT only.
FOLD' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.3  Med: -2.6 Max: 2.1
Current: -3.9
-16.3
2.1
EV-to-EBITDA -3.96
FOLD's EV-to-EBITDA is ranked lower than
99.99% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. FOLD: -3.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
FOLD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.6  Med: -2.7 Max: 4.1
Current: -3.96
-16.6
4.1
Current Ratio 2.59
FOLD's Current Ratio is ranked lower than
67% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. FOLD: 2.59 )
Ranked among companies with meaningful Current Ratio only.
FOLD' s Current Ratio Range Over the Past 10 Years
Min: 2.59  Med: 7.48 Max: 21.6
Current: 2.59
2.59
21.6
Quick Ratio 2.55
FOLD's Quick Ratio is ranked lower than
64% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. FOLD: 2.55 )
Ranked among companies with meaningful Quick Ratio only.
FOLD' s Quick Ratio Range Over the Past 10 Years
Min: 2.55  Med: 7.48 Max: 21.6
Current: 2.55
2.55
21.6
Days Inventory 731.06
FOLD's Days Inventory is ranked lower than
98% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. FOLD: 731.06 )
Ranked among companies with meaningful Days Inventory only.
FOLD' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0 Max: 731.06
Current: 731.06
0
731.06
Days Sales Outstanding 148.27
FOLD's Days Sales Outstanding is ranked lower than
84% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. FOLD: 148.27 )
Ranked among companies with meaningful Days Sales Outstanding only.
FOLD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.94  Med: 85.88 Max: 1088.97
Current: 148.27
63.94
1088.97

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -36.10
FOLD's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. FOLD: -36.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
FOLD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -317.5  Med: -36.1 Max: -15.3
Current: -36.1
-317.5
-15.3

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 13.93
FOLD's Price/Median PS Value is ranked lower than
97% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. FOLD: 13.93 )
Ranked among companies with meaningful Price/Median PS Value only.
FOLD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.03  Med: 0.55 Max: 117.92
Current: 13.93
0.03
117.92
Earnings Yield (Greenblatt) (%) -25.60
FOLD's Earnings Yield (Greenblatt) (%) is ranked lower than
75% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. FOLD: -25.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
FOLD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -25.6  Med: 98.9 Max: 913.7
Current: -25.6
-25.6
913.7

More Statistics

Revenue (TTM) (Mil) $2.13
EPS (TTM) $ -1.43
Beta1.74
Short Percentage of Float42.82%
52-Week Range $4.41 - 9.83
Shares Outstanding (Mil)142.69

Analyst Estimate

Dec16
Revenue (Mil $)
EPS ($) -0.76
EPS w/o NRI ($) -0.76
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:FOLD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 16 2017
Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium™... Feb 15 2017
Amicus Therapeutics Updates Migalastat Drug Feb 15 2017
AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 15 2017
Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe... Feb 15 2017
Amicus Therapeutics Highlights New Fabry Program Data at WORLDSymposium™ 2017 Feb 14 2017
AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 09 2017
Amicus Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference Feb 06 2017
Biotech Premarket Movers: Amicus Therapeutics, Nantkwest and Organovo Jan 24 2017
Amicus Therapeutics Announces Presentations and Posters at 13th Annual WORLDSymposium™ 2017 Jan 24 2017
Amicus Therapeutics upgraded by Robert W. Baird Jan 24 2017
Amicus Therapeutics Provides Full-Year 2017 Strategic Outlook and Financial Guidance Jan 09 2017
AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 09 2017
Huge Energy Trade Kicks Off 2017 Insider Buying: DCP Midstream, Och-Ziff Capital, TransEnterix,... Jan 08 2017
National Institute for Health and Care Excellence (NICE) Issues Final Positive Recommendation for... Jan 04 2017
5 Stocks Insiders Love Right Now Jan 01 2017
AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Dec 30 2016
Amicus Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference Dec 23 2016
Abercrombie, OvaScience Slide Into Thursday’s 52-Week Low Club Dec 22 2016
Amicus Therapeutics, Inc. (FOLD) Announces The Closure Of Its Senior Convertible Notes Dec 22 2016
AMICUS THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination... Dec 21 2016
Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full... Dec 21 2016
Amicus Therapeutics Announces Closing of Offering of Senior Convertible Notes and Exercise in Full... Dec 21 2016
Amicus Therapeutics Announces Pricing of Offering of Convertible Senior Notes Dec 15 2016
Amicus Therapeutics to Announce Second Quarter 2016 Financial Results on August 9, 2016 Aug 09 2016
Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors Jun 09 2016
Amicus' Fabry disease drug gets European Commission approval May 31 2016
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016 May 03 2016
Amicus Therapeutics to Announce First Quarter 2016 Financial Results on May 3, 2016 Apr 26 2016
Amicus Therapeutics Receives Positive CHMP Opinion for Approval of Migalastat in Patients with Fabry... Apr 01 2016
Amicus Therapeutics Announces Expanded Access Program for Migalastat Mar 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)